Hims & Hers launches generic semaglutide in Canada at $149 monthly
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Hims & Hers Expands GLP-1 Offering in Canada with Generic Semaglutide
May 21, 2026 9:00 AM EDTBy introducing access to generic semaglutide in Canada, the company is meeting the needs of a dynamic market and continuing its international expansion efforts
SAN FRANCISCO--(BUSINESS WIRE)-- Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced the availability of generic semaglutide through its platform in Canada. This is Hims & Hers first international generic GLP-1 offering, demonstrating the companys ability to meet the unique needs of each global market it serves while continuing its international expansion efforts. Personalized treatment plans are available starting at... More
